Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Down 40.6% in October

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 10,100 shares, a drop of 40.6% from the October 15th total of 17,000 shares. Based on an average daily volume of 437,600 shares, the short-interest ratio is currently 0.0 days. Approximately 1.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a report on Saturday. They issued a “sell” rating on the stock.

Titan Pharmaceuticals Trading Up 1.3 %

Titan Pharmaceuticals stock opened at $4.42 on Wednesday. The stock has a 50-day moving average price of $4.92 and a 200 day moving average price of $5.75. Titan Pharmaceuticals has a 52 week low of $3.57 and a 52 week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.